Regentis Biomaterials Ltd. (NYSE American: RGNT) is positioning its Gelrin C hydrogel as a practical regenerative medicine solution for cartilage damage that could help address the substantial clinical and economic burden associated with knee osteoarthritis (OA). Gelrin C is a cell-free, off-the-shelf hydrogel administered in a single 10-minute procedure, designed to support cartilage regeneration while avoiding the multiple surgeries, specialized laboratory processing and higher costs associated with some cell-based therapies.
With approximately 470,000 knee cartilage repair procedures performed annually in the U.S., representing an estimated $3 billion market, the company believes Gelrin C could offer a more scalable approach that fits existing surgical workflows and addresses cartilage defects before they progress to costly OA. The annual U.S. economic burden of knee OA ranges from approximately $5.7 billion to $15 billion, with lifetime costs for affected patients potentially exceeding $140,000, according to estimates highlighted in the article.
As Regentis advances Gelrin C toward commercialization, its single-stage design, proprietary hydrogel technology and clinical data could position the company to benefit from growing demand for regenerative treatments that preserve joint health and potentially delay or prevent more expensive degenerative disease. The full article is available at https://ibn.fm/yPKU2.
Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis’ lead product GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.
This content has been disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid investor awareness and marketing engagement. For the latest news and updates relating to RGNT, visit the company’s newsroom at https://ibn.fm/RGNT.
